Details for Patent: 6,967,208

Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS and is included in one NDA.

This patent has seventy-four patent family members in thirty-six countries.

Summary for Patent: 6,967,208

Title:	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:	The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s):	Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee:	Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:	10/245,122
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,967,208
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,967,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y	Y		PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y	Y		REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y	Y		TREATMENT OF PULMONARY EMBOLISM (PE)
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y	Y		REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y	Y		REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM

International Family Members for US Patent 6,967,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1427415		C300500	Netherlands
European Patent Office	1427415		C20110017 00045	Estonia
European Patent Office	1427415		CA 2011 00028	Denmark
European Patent Office	1427415		91888	Luxembourg
European Patent Office	1427415		1190029-7	Sweden